Income Statement
SENSEI BIOTHERAPEUTICS, INC.
SNSE
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
22.29 | 32.61 | 37.06 | 50.19 | 37.48 |
|
Research & Development
|
- | - | - | - | - |
|
Selling, General & Administrative
|
11.33 | 13.04 | 18.77 | 19.81 | 15.82 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-22.29 | -32.61 | -37.06 | -50.19 | -37.48 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
0.03 | 0.09 | 0.14 | 0.22 | 0.67 |
|
Other Non-Op Income / Expense
|
0.00 | 0.00 | -0.22 | 0.04 | - |
|
Income Before Tax
|
-21.09 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-21.09 | -30.16 | -34.10 | -48.59 | -36.79 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-22.17 | -32.01 | -36.46 | -49.57 | -36.80 |
|
Earnings Per Share (Basic)
|
-16.72 | -1.20 | -1.22 | -1.58 | - |
|
Diluted EPS
|
-16.72 | -1.20 | -1.22 | -1.58 | - |
|
Weighted Average Shares
|
1.26 | 25.12 | 27.95 | 30.70 | - |
|
Diluted Weighted Avg Shares
|
1.26 | 25.12 | 27.95 | 30.70 | - |
|
Comprehensive Income
|
-21.07 | -29.96 | -33.31 | -49.26 | -37.13 |